Kuros Biosciences hit three advancements for its MagnetOS portfolio, according to a Jan. 4 news release. 

Ossium Health's OssiGraft viable bone matrix allograft was used in its first patient case, according to a Dec. 14 news release.

Legislation has been introduced in the U.S. House that would require all bone graft material to be tested for active and latent tuberculosis. It would also expedite the process for developing a screening test, according to a Dec. 13 report from The Detroit News. 

Medical device company Alafair Biosciences has surpassed 12,000 implantations of its flagship product VersaWrap, the only class II medical device intended for use on tendon, ligament, skeletal muscle and peripheral nerve, including on nerve root in spine procedures. 

Orthopedic devicemaker Paragon 28 launched the Beast cortical fibers, the company said Nov. 14.

Here are three key updates on spine and orthopedic biologics since Oct. 10.

David Karli, MD, has opened an orthopedic regenerative medicine center focusing on bone marrow concentrate and micronized fat stem cell therapies in Miami, Fla.

Regenerative orthopedic developer Advanced Biologics has merged with orthobiologic firm Isto Biologics, according to an Oct. 24 report from the North Coast Current.

DiscGenics is partnering with the U.S. Department of Veterans Affairs to conduct research into forming tissue-engineered discs, according to an Oct. 18 news release.

Orthofix earned FDA 510(k) clearance for its OsteoCove advance bioactive synthetic graft, the company said Oct. 12.

Here are 11 key updates on orthobiologics from the third quarter of 2023:

Researchers at New York City-based Hospital for Special Surgery and Weill Cornell Medicine discovered a new stem cell that could affect spine care.

Creative Medical Technology Holdings got FDA clearance for its Phase 1/2 clinical trial for its StemSpine procedure using AlloStem, according to a Sept. 19 news release.

Here are five updates on orthopedic regenerative medicine Becker's has reported on since Aug. 15: 

In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.

HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.

A group of lawmakers wrote a letter to Robert Califf, MD, the U.S. FDA commissioner, pushing for stricter guidance for bone grafts in light of a recent spate of tuberculosis linked to orthopedic products.

The consensus on whether regenerative medicine is effective in sports medicine is still up in the air, according to Michael Ciccotti, MD, of Rothman Orthopaedic Institute in Philadelphia.

A Michigan woman died from tuberculosis linked to tainted bone graft, The Detroit News reported Aug, 18.

Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.